Item 7.01. Regulation FD Disclosure.

On January 10, 2020, CURE Pharmaceutical Holding Corp. (the "Company") updated its website (http://bit.ly/curecoeptisupdate) to include an update to information previously filed on November 14, 2019 with the Securities and Exchange Commission on a Current Report on Form 8-K (the "Original Form 8-K").

In the Original Form 8-K, the Company announced that the Company and Coeptis Pharmaceuticals, Inc. ("Coeptis") entered into a non-binding term sheet contemplating that the Company and Coeptis will enter into a Merger Agreement pursuant to which a wholly-owned subsidiary of the Company will merge into Coeptis so that Coeptis will become a wholly-owned subsidiary of the Company with the final terms and valuation to be determined based on certain contingent events.

The Company announced that despite the strategic merits of the proposed transaction, the parties were unable to arrive at mutually agreeable terms to complete the acquisition and negotiations related to the acquisition have terminated.

The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits



Exhibit Number   Description
  99.1             Company webpage at http://bit.ly/curecoeptisupdate





2

© Edgar Online, source Glimpses